PharmTech News

Articles

Novartis entered separate license agreements with bluebird bio and Celyad for patents related to the manufacture of CAR-T cells. 


Novartis Licenses CAR-T Patents in Separate Deals

The drug is approved to treat postmenopausal women with osteoporosis and is the first anabolic bone building agent approved in the US in approximately 15 years. 

FDA Approves Radius Health’s Tymlos to Treat Osteoporosis

With two acquisitions, German company Fresenius Kabi enters biosimilars market and expands in US.


Fresenius Kabi Acquires Merck KGaA’s Biosimilars Business and US-Based Akorn

On April 24, 2017, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and a group of executives from several big pharma companies composed an open letter to the European Medicines Agency (EMA) regarding its relocation.

Pharma Execs Compose Open Letter on EMA Relocation

Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.

Sanofi filed an antitrust lawsuit with a district court in New Jersey alleging Mylan took steps to restrict access to a competing epinephrine autoinjector.

Sanofi Hits Mylan with Anti-Trust Lawsuit

Valeant’s Siliq (brodalumab) injection will be listed for $3500 a month in the United States, the company said on April 21, 2017. In a statement, Valeant said this makes Siliq the lowest-priced injectable biologic to treat psoriasis on the US market.

Valeant Announces List Price of Brodalumab

Amgen is once again asking the court to weigh in on a patent infringement case. In March 2017, Sanofi and Regeneron asked a federal court to issue a declaratory judgment of non-infringement indicating that their drug Dupixent (dupilumab) does not infringe on Amgen’s ‘487 patent covering IL-4 inhibitors. Although the court has not yet responded to this request, in early April 2017 Amgen issued a complaint of patent infringement against Sanofi/Regeneron involving the same ‘487 patent.

Amgen Asks Court to Weigh in on Dupixent, Claims Infringement

The agency approved Renflexis, a biosimilar to Janssen’s blockbuster rheumatoid arthritis treatment.

FDA Approves Second Biosimilar to Remicade

On April 20, 2017 UniQure announced that it will not pursue marketing authorization renewal in the European Union for Glybera (alipogene tiparvovec), the first gene-therapy approved by EMA. Glybera’s marketing authorization is set to expire on Oct. 25, 2017.

uniQure Will Not Renew Marketing Authorization of Glybera

Cobra will increase capacity in response to customer demand for DNA and viral vector production.

Bio/Pharma News